JUPITER, Fla.--(BUSINESS WIRE)--BioCurity, a private preclinical biotech, is developing oncology supportive care drugs that are designed to prevent or mitigate some of the side effects associated with radiation therapy. Today, BioCurity announced it has filed a US provisional patent application entitled “Improved Cerium Oxide Nanoparticles Formulations” on April 9, 2021 (U.S. Provisional Application No. 63172912).
BioCurity’s proposed drugs generated from the company’s cerium oxide nanoparticle technology include a topical formulation for the protection of skin and an intravenous (IV) formulation for the protection of normal internal tissue from radiation damage without impacting the effectiveness of radiation treatment. “The ability to administer the planned dose of radiation therapy, while preventing radiation induced cytotoxicity has the potential to improve patient quality of life and reduce overall healthcare costs,” stated Jim Sergi, President and Founder, CSSi LifeSciences.
The U.S. provisional patent application was filed with the U.S. Patent and Trademark Office and relates to BioCurity’s new and improved topical and intravenous pharmaceutical formulations containing cerium oxide nanoparticles. The patent application, once converted into a U.S. non-provisional, utility application, will provide composition of matter for topical and IV formulations of cerium oxide nanoparticles, effective upon a grant of a U.S. patent. BioCurity also plans to pursue an international (PCT) application, from which national stage patent applications can be submitted in both industrial jurisdictions and developing countries around the world. A provisional patent application offers a patent applicant an option of filing without including a formal patent claim. The aim of a provisional patent application is to establish an early effective filing date, in addition to allowing the patent applicant or a licensee to ascribe the phrase “patent pending” to any commercial products, methods, or services contemplated by the subject matter claimed.
About BioCurity Pharmaceuticals Inc.
BioCurity is a private preclinical biotech company with a mission to prevent radiation therapy's side effects for cancer patients. Globally, approximately 6 million of the 18 million annually diagnosed new cancer patients receive radiation. The lack of a drug to protect cancer patients' internal tissues and skin from the short and long-term side effects of radiation therapy is a global unmet patient need. Invest in BioCurity through its Regulation Crowdfunding Campaign to support its drug development. Visit BioCurity's website and follow them on LinkedIn and Facebook.
This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the "Company" or "BioCurity"), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity's lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.